Abstract：
BACKGROUND: Coronavirus 2019 symptoms include coagulopathy and thromboembolic risk. Using one parameter to diagnose coagulopathy has little predictive value.
OBJECTIVE: This study will examine if D-dimer and APTT testing can predict COVID-19 severity and aid triage and manage patients.
METHODS: 214 COVID-19 patients were enrolled and classified into two categories based on their respiratory manifestations; mild (126 cases) and severe (88 cases). Patient data regarding age, gender, D-Dimer level, and APTT level were collected. When both D-Dimer and APTT levels were abnormal, in this study, the patient was considered to have a coagulation disorder. Indicators of coagulation in the COVID-19 patients were collected and compared between the two groups. Chi-square (χ2) tests were used to determine the significant differences between coagulation disorders in the two groups.
RESULTS: Our findings showed that patients with coagulopathies were more likely to belong to the severe group. Within the two groups of patients, the rate of coagulation disorders was as follows: mild = 8.8 % within coagulation disorders, 4.8% within the two Groups; severe = 91.2 % within coagulation disorders, 77.8 % within the two Groups. There was a statistically significant relationship between coagulation disorder and severe COVID-19 patients compared to mild patients (p < 0.05).
CONCLUSIONS: Coagulation disorders are more likely to occur in severe COVID-19 patients. D-Dimer and APTT tests are significant indicators for predicting COVID-19 severity. Our research found an abnormal pattern of coagulation disorders and COVID-19 severity that should be considered in the COVID-19 treatment protocol.
OBJECTIVE: This study will examine if D-dimer and APTT testing can predict COVID-19 severity and aid triage and manage patients.
METHODS: 214 COVID-19 patients were enrolled and classified into two categories based on their respiratory manifestations; mild (126 cases) and severe (88 cases). Patient data regarding age, gender, D-Dimer level, and APTT level were collected. When both D-Dimer and APTT levels were abnormal, in this study, the patient was considered to have a coagulation disorder. Indicators of coagulation in the COVID-19 patients were collected and compared between the two groups. Chi-square (χ2) tests were used to determine the significant differences between coagulation disorders in the two groups.
RESULTS: Our findings showed that patients with coagulopathies were more likely to belong to the severe group. Within the two groups of patients, the rate of coagulation disorders was as follows: mild = 8.8 % within coagulation disorders, 4.8% within the two Groups; severe = 91.2 % within coagulation disorders, 77.8 % within the two Groups. There was a statistically significant relationship between coagulation disorder and severe COVID-19 patients compared to mild patients (p < 0.05).
CONCLUSIONS: Coagulation disorders are more likely to occur in severe COVID-19 patients. D-Dimer and APTT tests are significant indicators for predicting COVID-19 severity. Our research found an abnormal pattern of coagulation disorders and COVID-19 severity that should be considered in the COVID-19 treatment protocol.
摘要：
背景：2019年冠状病毒症状包括凝血功能障碍和血栓栓塞风险。使用一个参数来诊断凝血病几乎没有预测价值。
目的：本研究将研究D-二聚体和APTT检测是否可以预测COVID-19的严重程度，并帮助患者分诊和管理。
方法：214例COVID-19患者根据其呼吸道表现分为轻度（126例）和重度（88例）两类。关于年龄的患者数据，性别,D-二聚体水平,收集APTT水平。当D-二聚体和APTT水平都异常时，在这项研究中，患者被认为患有凝血障碍.收集并比较两组患者的凝血指标。使用卡方（χ2）检验确定两组凝血障碍之间的显着差异。
结果：我们的研究结果表明，有凝血障碍的患者更可能属于重症组。在两组患者中，凝血障碍的发生率如下：轻度=凝血障碍中的8.8％，两组中有4.8％；严重=凝血障碍中的91.2％，两组中77.8%。与轻度患者相比，凝血障碍与重度COVID-19患者之间存在统计学上的显着关系（p<0.05）。
结论：重症COVID-19患者更容易发生凝血障碍。D-Dimer和APTT测试是预测COVID-19严重程度的重要指标。我们的研究发现凝血障碍和COVID-19严重程度的异常模式，应在COVID-19治疗方案中予以考虑。
目的：本研究将研究D-二聚体和APTT检测是否可以预测COVID-19的严重程度，并帮助患者分诊和管理。
方法：214例COVID-19患者根据其呼吸道表现分为轻度（126例）和重度（88例）两类。关于年龄的患者数据，性别,D-二聚体水平,收集APTT水平。当D-二聚体和APTT水平都异常时，在这项研究中，患者被认为患有凝血障碍.收集并比较两组患者的凝血指标。使用卡方（χ2）检验确定两组凝血障碍之间的显着差异。
结果：我们的研究结果表明，有凝血障碍的患者更可能属于重症组。在两组患者中，凝血障碍的发生率如下：轻度=凝血障碍中的8.8％，两组中有4.8％；严重=凝血障碍中的91.2％，两组中77.8%。与轻度患者相比，凝血障碍与重度COVID-19患者之间存在统计学上的显着关系（p<0.05）。
结论：重症COVID-19患者更容易发生凝血障碍。D-Dimer和APTT测试是预测COVID-19严重程度的重要指标。我们的研究发现凝血障碍和COVID-19严重程度的异常模式，应在COVID-19治疗方案中予以考虑。
